« Previous
Next »
Biology of Blood and Marrow Transplantation
Volume 15, Issue 12
, Pages
1563-1570
, December 2009
A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of Deescalation
-
Kaplan-Meier estimated incidences of aGVHD grade II-IV and grade III-IV.
Kaplan-Meier estimated incidences of aGVHD grade II-IV and grade III-IV.
-
(a,b) Kaplan-Meier estimated incidences of aGVHD grade II-IV and grade III-IV in comparison with graft source (SIB/UD).
(a,b) Kaplan-Meier estimated incidences of aGVHD grade II-IV and grade III-IV in comparison with graft source (SIB/UD).
-
Kaplan-Meier estimated incidences of overall and extensive cGVHD.
Kaplan-Meier estimated incidences of overall and extensive cGVHD.
-
Kaplan-Meier estimated incidence of relapse.
Kaplan-Meier estimated incidence of relapse.
-
Kaplan-Meier estimated incidence of NRM.
Kaplan-Meier estimated incidence of NRM.
-
Kaplan-Meier estimation for OS.
Kaplan-Meier estimation for OS.
Present address for Alexandros Spyridonidis: Patras University Medical, School Rion/Patras 26500 Greece.
Present address for Carsten Grüllich: National Cancer Center Heidelberg, Deparetment of Translational Oncology, D-69120 Heidelberg, Germany.
Financial disclosure: See Acknowledgments on page 1569.
PII: S1083-8791(09)00366-8
doi: 10.1016/j.bbmt.2009.08.002
© 2009 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Biology of Blood and Marrow Transplantation
Volume 15, Issue 12
, Pages
1563-1570
, December 2009
